PL360704A1 - Doustny szybko rozpuszczalny preparat inhibitora cyklooksygenazy-2 - Google Patents
Doustny szybko rozpuszczalny preparat inhibitora cyklooksygenazy-2Info
- Publication number
- PL360704A1 PL360704A1 PL36070401A PL36070401A PL360704A1 PL 360704 A1 PL360704 A1 PL 360704A1 PL 36070401 A PL36070401 A PL 36070401A PL 36070401 A PL36070401 A PL 36070401A PL 360704 A1 PL360704 A1 PL 360704A1
- Authority
- PL
- Poland
- Prior art keywords
- oral fast
- cyclooxygenase
- granules
- blending
- inhibitor
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 title 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 2
- 239000008187 granular material Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000002156 mixing Methods 0.000 abstract 2
- 229920000881 Modified starch Polymers 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000000783 alginic acid Substances 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- 229960001126 alginic acid Drugs 0.000 abstract 1
- 150000004781 alginic acids Chemical class 0.000 abstract 1
- 235000012216 bentonite Nutrition 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 235000019426 modified starch Nutrition 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920000193 polymethacrylate Polymers 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000004760 silicates Chemical class 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22634700P | 2000-08-18 | 2000-08-18 | |
| PCT/US2001/025803 WO2002015885A2 (en) | 2000-08-18 | 2001-08-17 | Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL360704A1 true PL360704A1 (pl) | 2004-09-20 |
Family
ID=22848576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL36070401A PL360704A1 (pl) | 2000-08-18 | 2001-08-17 | Doustny szybko rozpuszczalny preparat inhibitora cyklooksygenazy-2 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20020049233A1 (pl) |
| EP (2) | EP1355631B1 (pl) |
| JP (2) | JP2004506681A (pl) |
| KR (1) | KR20030045035A (pl) |
| CN (1) | CN1638739A (pl) |
| AT (1) | ATE374599T1 (pl) |
| AU (3) | AU2001286530B2 (pl) |
| BR (1) | BR0113293A (pl) |
| CA (2) | CA2418730A1 (pl) |
| CZ (1) | CZ2003422A3 (pl) |
| DE (1) | DE60130801T2 (pl) |
| DK (1) | DK1355631T3 (pl) |
| ES (1) | ES2292614T3 (pl) |
| IL (1) | IL154386A0 (pl) |
| MX (2) | MXPA03001346A (pl) |
| NO (1) | NO20030727L (pl) |
| NZ (2) | NZ524115A (pl) |
| PL (1) | PL360704A1 (pl) |
| PT (1) | PT1355631E (pl) |
| WO (2) | WO2002015885A2 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002303577B2 (en) * | 2001-05-04 | 2006-06-08 | Merck & Co., Inc. | Method and compositions for treating migraines |
| MXPA04002798A (es) * | 2001-09-26 | 2004-07-05 | Pharmacia Corp | Composiciones de valdecoxib de disgregacion intraoral. |
| BR0213152A (pt) * | 2001-10-10 | 2004-10-19 | Pharmacia Corp | Composições de valdecoxib de desintegração intraoral preparadas por processo de secagem por pulverização |
| JP2005512990A (ja) * | 2001-11-07 | 2005-05-12 | ファルマシア・コーポレーション | 流動層造粒法により製造される口腔内崩壊型バルデコキシブ組成物 |
| US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| WO2006052503A2 (en) * | 2004-11-04 | 2006-05-18 | Merck & Co Inc | Process for granulating particles |
| JP4945917B2 (ja) * | 2005-01-19 | 2012-06-06 | 大正製薬株式会社 | 薬物含有コーティング用核粒子 |
| EP2932982B1 (en) * | 2005-05-17 | 2018-10-03 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| JP2008518041A (ja) * | 2005-08-29 | 2008-05-29 | テバ ファーマシューティカル インダストリーズ リミティド | 双峰性粒度分布を有する固体微粒子タダラフィル |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| CA2632039A1 (en) * | 2005-12-23 | 2007-06-28 | Lek Pharmaceuticals D.D. | Bursting pellets |
| US20100233272A1 (en) * | 2007-11-15 | 2010-09-16 | Leah Elizabeth Appel | Dosage forms comprising celecoxib providing both rapid and sustained pain relief |
| KR20200032244A (ko) | 2012-03-07 | 2020-03-25 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물 |
| CN104027319A (zh) * | 2014-06-25 | 2014-09-10 | 万特制药(海南)有限公司 | 一种塞来昔布分散片及其制备方法 |
| WO2016054231A1 (en) | 2014-09-30 | 2016-04-07 | Amicus Therapeutics, Inc. | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
| KR102510941B1 (ko) | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| US10227577B2 (en) | 2016-03-30 | 2019-03-12 | Amicus Therapeutics, Inc. | Method for selection of high M6P recombinant proteins |
| IL325155A (en) | 2016-03-30 | 2026-02-01 | Amicus Therapeutics Inc | Formulations containing recombinant acid alpha-glucosidase |
| EP3624831B1 (en) | 2017-05-15 | 2023-03-29 | Amicus Therapeutics, Inc. | Recombinant human acid alpha-glucosidase |
| US10350171B2 (en) | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
| CN108576205B (zh) * | 2018-03-22 | 2022-01-04 | 湖北省农业科学院农产品加工与核农技术研究所 | 一种草莓联合干燥的处理方法 |
| CA3119728A1 (en) * | 2018-11-21 | 2020-05-28 | Tremeau Pharmaceuticals, Inc. | Purified forms of rofecoxib, methods of manufacture and use |
| JP2020183359A (ja) * | 2019-05-09 | 2020-11-12 | 日医工株式会社 | セレコキシブ含有医薬組成物 |
| US10945992B1 (en) | 2019-11-13 | 2021-03-16 | Tremeau Pharmaceuticals, Inc. | Dosage forms of rofecoxib and related methods |
| US20240000705A1 (en) * | 2020-09-17 | 2024-01-04 | Catalent U.K. Swindon Zydis Limited | Use of surfactant with high molecular weight fish gelatin based dosage formulations to improve flow characteristics |
| US11161833B1 (en) | 2021-04-09 | 2021-11-02 | Tremeau Pharmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture, and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3122141B2 (ja) * | 1994-01-31 | 2001-01-09 | 山之内製薬株式会社 | 口腔内溶解型圧縮成型物及びその製造法 |
| US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| SK74396A3 (en) * | 1995-06-13 | 1997-04-09 | American Home Prod | Organoleptically acceptable oral pharmaceutical compositions |
| CN1140267C (zh) * | 1996-05-17 | 2004-03-03 | 麦克公司 | 治疗环加氧酶-2介导的疾病的每天一次的组合物 |
| EP0839526A3 (en) * | 1996-10-31 | 1999-01-07 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation with fast buccal disintegration or dissolution |
| IT1293764B1 (it) * | 1997-07-23 | 1999-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua |
| US6465009B1 (en) * | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
| SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| JP2003516353A (ja) * | 1999-12-08 | 2003-05-13 | ファルマシア コーポレイション | ヴァルデコキシブ組成物 |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| WO2002067894A2 (en) * | 2001-02-27 | 2002-09-06 | Ranbaxy Laboratories Limited | Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors |
-
2001
- 2001-08-13 CN CN01814092.0A patent/CN1638739A/zh active Pending
- 2001-08-17 NZ NZ524115A patent/NZ524115A/en unknown
- 2001-08-17 EP EP01965984A patent/EP1355631B1/en not_active Expired - Lifetime
- 2001-08-17 MX MXPA03001346A patent/MXPA03001346A/es not_active Application Discontinuation
- 2001-08-17 CA CA002418730A patent/CA2418730A1/en not_active Abandoned
- 2001-08-17 AT AT01965984T patent/ATE374599T1/de not_active IP Right Cessation
- 2001-08-17 PT PT01965984T patent/PT1355631E/pt unknown
- 2001-08-17 JP JP2002520808A patent/JP2004506681A/ja not_active Withdrawn
- 2001-08-17 CZ CZ2003422A patent/CZ2003422A3/cs unknown
- 2001-08-17 AU AU2001286530A patent/AU2001286530B2/en not_active Ceased
- 2001-08-17 DK DK01965984T patent/DK1355631T3/da active
- 2001-08-17 US US09/932,500 patent/US20020049233A1/en not_active Abandoned
- 2001-08-17 IL IL15438601A patent/IL154386A0/xx unknown
- 2001-08-17 AU AU8653001A patent/AU8653001A/xx active Pending
- 2001-08-17 PL PL36070401A patent/PL360704A1/pl not_active Application Discontinuation
- 2001-08-17 MX MXPA03001408A patent/MXPA03001408A/es not_active Application Discontinuation
- 2001-08-17 WO PCT/US2001/025803 patent/WO2002015885A2/en not_active Ceased
- 2001-08-17 EP EP01965987A patent/EP1309316A2/en not_active Withdrawn
- 2001-08-17 BR BR0113293-8A patent/BR0113293A/pt not_active Application Discontinuation
- 2001-08-17 NZ NZ524123A patent/NZ524123A/en unknown
- 2001-08-17 CA CA002420190A patent/CA2420190A1/en not_active Abandoned
- 2001-08-17 ES ES01965984T patent/ES2292614T3/es not_active Expired - Lifetime
- 2001-08-17 WO PCT/US2001/025834 patent/WO2002015886A2/en not_active Ceased
- 2001-08-17 KR KR10-2003-7002392A patent/KR20030045035A/ko not_active Ceased
- 2001-08-17 JP JP2002520807A patent/JP2004512274A/ja not_active Withdrawn
- 2001-08-17 DE DE60130801T patent/DE60130801T2/de not_active Expired - Fee Related
- 2001-08-17 AU AU2001286533A patent/AU2001286533A1/en not_active Abandoned
-
2003
- 2003-02-14 NO NO20030727A patent/NO20030727L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002015886A2 (en) | 2002-02-28 |
| ES2292614T3 (es) | 2008-03-16 |
| JP2004506681A (ja) | 2004-03-04 |
| PT1355631E (pt) | 2007-11-29 |
| MXPA03001408A (es) | 2005-06-30 |
| US20020049233A1 (en) | 2002-04-25 |
| CN1638739A (zh) | 2005-07-13 |
| IL154386A0 (en) | 2003-09-17 |
| CA2418730A1 (en) | 2002-02-28 |
| AU8653001A (en) | 2002-03-04 |
| NZ524123A (en) | 2005-02-25 |
| KR20030045035A (ko) | 2003-06-09 |
| WO2002015885A2 (en) | 2002-02-28 |
| DE60130801T2 (de) | 2008-06-26 |
| EP1309316A2 (en) | 2003-05-14 |
| CA2420190A1 (en) | 2002-02-28 |
| EP1355631A2 (en) | 2003-10-29 |
| MXPA03001346A (es) | 2003-06-06 |
| ATE374599T1 (de) | 2007-10-15 |
| JP2004512274A (ja) | 2004-04-22 |
| AU2001286530B2 (en) | 2007-01-25 |
| NO20030727D0 (no) | 2003-02-14 |
| WO2002015886A3 (en) | 2002-07-25 |
| DK1355631T3 (da) | 2008-02-04 |
| CZ2003422A3 (cs) | 2003-06-18 |
| EP1355631B1 (en) | 2007-10-03 |
| WO2002015885A3 (en) | 2003-08-28 |
| AU2001286533A1 (en) | 2002-03-04 |
| BR0113293A (pt) | 2003-06-10 |
| NZ524115A (en) | 2004-10-29 |
| NO20030727L (no) | 2003-03-24 |
| DE60130801D1 (de) | 2007-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL154386A0 (en) | Oral fast-melt formulation of a cyclooxygenase-2 inhibitor | |
| TWI256305B (en) | Oral fast-melt pharmaceutical composition of a cyclooxygenase-2 inhibitor and process for preparing the same | |
| UA63993C2 (uk) | Фармацевтична лікарська форма, що швидко тане в роті (варіанти) та спосіб формування гранул | |
| HUP0400636A3 (en) | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof | |
| DZ3313A1 (fr) | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant | |
| HUP0301932A3 (en) | Benzophenones as inhibitors of il-1 beta and tnf-alpha, pharmaceutical compositions containing them and use of them for producing pharmaceutical compositions | |
| WO2004100857A3 (en) | Highly plastic granules for making fast melting tablets | |
| HUP0203836A3 (en) | 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use | |
| MY127350A (en) | Flash-melt oral dose formulations | |
| WO2001032181A3 (en) | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum | |
| IS6630A (is) | 5-klór-3-(4-metansúlfónýlfenýl)-6'-metýl-[2,3']bípýridinýl á hreinu kristallaformi og aðferð til smíði þess | |
| CA2106216A1 (en) | Chewable antacid compositions | |
| ZA200108001B (en) | Processes for making pharmaceutical oral ECB formulations and compositions. | |
| HUP0400549A3 (en) | Novel imidazole derivatives, production method thereof and pharmaceutical compositions containing them | |
| HUP0204001A3 (en) | Substituted aminomethyl-phenyl-cyclohexane derivatives, process for their preparation and pharmaceutical compositions containing them | |
| AU2002341555A1 (en) | Levothyroxine pharmaceutical compositions, methods of making and methods of administration | |
| IL157539A0 (en) | A stable pharmaceutical formulation comprising torsemide modification ii | |
| WO2003013441A3 (en) | Levothyroxine compositions and methods | |
| HUP0302905A3 (en) | Triazolo-epothilone-analogs, process for their preparation and pharmaceutical compositions containing them | |
| HUP0204422A3 (en) | Calcium dicarboxylate ethers, methods of making the compounds, and pharmaceutical compositions containing them | |
| WO2004014318A3 (en) | Levothyroxine compositions and methods | |
| HUP0100749A3 (en) | New 6-amino- or 6-hydrazino-sulphonyl-3-quinolinyl-phosphonic acid derivatives, process for their preparation and pharmaceutical compositions containing them | |
| ZA200303307B (en) | Oral pharmaceutical composition containing a block copolymer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |